# LENSAR, Inc.: financial statements, quarterly

LNSR · Nasdaq · CIK 1320350 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/lnsr.md) · [Financials](/companies/lnsr/financials.md) · [Filings](/companies/lnsr/filings.md) · [Insiders](/companies/lnsr/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/lnsr/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [8.3](/filings/0000950170-24-123534.md) | [10.5 d](/filings/0000950170-25-029003.md) | [8.6](/filings/0000950170-25-066964.md) | [10.7](/filings/0001320350-25-000004.md) | [11.8](/filings/0001193125-25-269428.md) | [14.8 d](/filings/0001193125-26-134587.md) | [12.3](/filings/0001193125-26-214571.md) | [12.3](/filings/0001193125-26-349315.md) | [12.8](/filings/0001193125-25-269428.md) | [14.3 d](/filings/0001193125-26-134587.md) | [11.7](/filings/0001193125-26-214571.md) | [14.7](/filings/0001193125-26-349315.md) |
| Cost of revenue | $m | [4.9](/filings/0000950170-24-123534.md) | [7.0 d](/filings/0000950170-25-029003.md) | [4.9](/filings/0000950170-25-066964.md) | [5.8](/filings/0001320350-25-000004.md) | [7.3](/filings/0001193125-25-269428.md) | [9.6 d](/filings/0001193125-26-134587.md) | [7.0](/filings/0001193125-26-214571.md) | [6.9](/filings/0001193125-26-349315.md) | [8.3](/filings/0001193125-25-269428.md) | [9.1 d](/filings/0001193125-26-134587.md) | [7.0](/filings/0001193125-26-214571.md) | [6.7](/filings/0001193125-26-349315.md) |
| Research and development | $m | [1.5](/filings/0000950170-24-123534.md) | [1.5 d](/filings/0000950170-25-029003.md) | [1.4](/filings/0000950170-25-066964.md) | [1.3](/filings/0001320350-25-000004.md) | [1.2](/filings/0001193125-25-269428.md) | [1.3 d](/filings/0001193125-26-134587.md) | [1.5](/filings/0001193125-26-214571.md) | [1.4](/filings/0001193125-26-349315.md) | [1.4](/filings/0001193125-25-269428.md) | [1.3 d](/filings/0001193125-26-134587.md) | [1.4](/filings/0001193125-26-214571.md) | [1.3](/filings/0001193125-26-349315.md) |
| Selling, general and administrative | $m | [5.1](/filings/0000950170-24-123534.md) | [6.4 d](/filings/0000950170-25-029003.md) | [6.8](/filings/0000950170-25-066964.md) | [6.8](/filings/0001320350-25-000004.md) | [6.1](/filings/0001193125-25-269428.md) | [6.8 d](/filings/0001193125-26-134587.md) | [11.1](/filings/0001193125-26-214571.md) | [11.7](/filings/0001193125-26-349315.md) | [12.0](/filings/0001193125-25-269428.md) | [10.3 d](/filings/0001193125-26-134587.md) | [2.5](/filings/0001193125-26-214571.md) | [6.1](/filings/0001193125-26-349315.md) |
| Operating income | $m | [(2.0)](/filings/0000950170-24-123534.md) | [(3.0) d](/filings/0000950170-25-029003.md) | [(2.9)](/filings/0000950170-25-066964.md) | [(5.3)](/filings/0001320350-25-000004.md) | [(1.2)](/filings/0001193125-25-269428.md) | [(1.3) d](/filings/0001193125-26-134587.md) | [(5.8)](/filings/0001193125-26-214571.md) | [(6.3)](/filings/0001193125-26-349315.md) | [(7.6)](/filings/0001193125-25-269428.md) | [(4.9) d](/filings/0001193125-26-134587.md) | [2.2](/filings/0001193125-26-214571.md) | [2.1](/filings/0001193125-26-349315.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0000950170-24-123534.md) | not reported | [0.0](/filings/0000950170-25-066964.md) | [0.0](/filings/0001320350-25-000004.md) | [0.0](/filings/0001193125-25-269428.md) | not reported | [0.0](/filings/0001193125-26-214571.md) | [0.0](/filings/0001193125-26-349315.md) | [0.0](/filings/0001193125-25-269428.md) | not reported | [0.0](/filings/0001193125-26-214571.md) | [0.0](/filings/0001193125-26-349315.md) |
| Net income | $m | [2.6](/filings/0000950170-24-123534.md) | [(3.9) d](/filings/0000950170-25-029003.md) | [(2.2)](/filings/0001193125-25-269428.md) | [(9.0)](/filings/0001193125-25-269428.md) | [(1.5)](/filings/0001193125-25-269428.md) | [(18.7) d](/filings/0001193125-26-134587.md) | [(27.3)](/filings/0001193125-26-349315.md) | [(1.8)](/filings/0001193125-26-349315.md) | [(3.7)](/filings/0001193125-25-269428.md) | [(1.5) d](/filings/0001193125-26-134587.md) | [36.3](/filings/0001193125-26-349315.md) | [3.5](/filings/0001193125-26-349315.md) |
| Diluted EPS | $ per share | [(0.23)](/filings/0000950170-24-123534.md) | not reported | [(0.19)](/filings/0000950170-25-066964.md) | [(0.79)](/filings/0001320350-25-000004.md) | [(0.13)](/filings/0001193125-25-269428.md) | not reported | [(2.32)](/filings/0001193125-26-214571.md) | [(0.15)](/filings/0001193125-26-349315.md) | [(0.31)](/filings/0001193125-25-269428.md) | not reported | [0.00](/filings/0001193125-26-214571.md) | [0.10](/filings/0001193125-26-349315.md) |
| Basic EPS | $ per share | [0.13](/filings/0000950170-24-123534.md) | not reported | [(0.19)](/filings/0000950170-25-066964.md) | [(0.79)](/filings/0001320350-25-000004.md) | [(0.13)](/filings/0001193125-25-269428.md) | not reported | [(2.32)](/filings/0001193125-26-214571.md) | [(0.15)](/filings/0001193125-26-349315.md) | [(0.31)](/filings/0001193125-25-269428.md) | not reported | [1.56](/filings/0001193125-26-214571.md) | [0.14](/filings/0001193125-26-349315.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Selling, general and administrative: us-gaap:SellingGeneralAndAdministrativeExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.9](/filings/0000950170-23-062153.md) | [20.6](/filings/0000950170-25-029003.md) | [14.0](/filings/0000950170-24-056837.md) | [8.3](/filings/0000950170-24-093862.md) | [10.4](/filings/0000950170-24-123534.md) | [16.3](/filings/0001193125-26-134587.md) | [19.5](/filings/0000950170-25-066964.md) | [7.2](/filings/0001320350-25-000004.md) | [7.6](/filings/0001193125-25-269428.md) | [13.0](/filings/0001193125-26-349315.md) | [12.5](/filings/0001193125-26-214571.md) | [13.6](/filings/0001193125-26-349315.md) |
| Current assets | $m | [48.6](/filings/0000950170-23-062153.md) | [46.4](/filings/0000950170-25-029003.md) | [42.4](/filings/0000950170-24-056837.md) | [40.2](/filings/0000950170-24-093862.md) | [39.4](/filings/0000950170-24-123534.md) | [42.0](/filings/0001193125-26-134587.md) | [49.2](/filings/0000950170-25-066964.md) | [45.9](/filings/0001320350-25-000004.md) | [44.4](/filings/0001193125-25-269428.md) | [46.8](/filings/0001193125-26-349315.md) | [42.4](/filings/0001193125-26-214571.md) | [47.0](/filings/0001193125-26-349315.md) |
| Total assets | $m | [70.9](/filings/0000950170-23-062153.md) | [69.6](/filings/0000950170-25-029003.md) | [66.1](/filings/0000950170-24-056837.md) | [61.4](/filings/0000950170-24-093862.md) | [62.0](/filings/0000950170-24-123534.md) | [66.3](/filings/0001193125-26-134587.md) | [73.0](/filings/0000950170-25-066964.md) | [70.4](/filings/0001320350-25-000004.md) | [70.2](/filings/0001193125-25-269428.md) | [71.4](/filings/0001193125-26-349315.md) | [66.2](/filings/0001193125-26-214571.md) | [69.6](/filings/0001193125-26-349315.md) |
| Current liabilities | $m | [11.0](/filings/0000950170-23-062153.md) | [11.6](/filings/0000950170-25-029003.md) | [10.4](/filings/0000950170-24-056837.md) | [10.4](/filings/0000950170-24-093862.md) | [11.7](/filings/0000950170-24-123534.md) | [15.0](/filings/0001193125-26-134587.md) | [27.2](/filings/0000950170-25-066964.md) | [30.1](/filings/0001320350-25-000004.md) | [35.7](/filings/0001193125-25-269428.md) | [40.6](/filings/0001193125-26-349315.md) | [17.8](/filings/0001193125-26-214571.md) | [19.6](/filings/0001193125-26-349315.md) |
| Total liabilities | $m | [20.7](/filings/0000950170-23-062153.md) | [22.4](/filings/0000950170-25-029003.md) | [20.6](/filings/0000950170-24-056837.md) | [24.0](/filings/0000950170-24-093862.md) | [25.5](/filings/0000950170-24-123534.md) | [47.7](/filings/0001193125-26-134587.md) | [81.3](/filings/0000950170-25-066964.md) | [79.7](/filings/0001320350-25-000004.md) | [82.3](/filings/0001193125-25-269428.md) | [83.7](/filings/0001193125-26-349315.md) | [41.6](/filings/0001193125-26-214571.md) | [40.9](/filings/0001193125-26-349315.md) |
| Shareholders' equity | $m | [36.4](/filings/0000950170-24-123534.md) | [33.4](/filings/0001193125-26-134587.md) | [31.8](/filings/0001193125-25-269428.md) | [23.6](/filings/0001193125-25-269428.md) | [22.7](/filings/0001193125-25-269428.md) | [4.9](/filings/0001193125-26-349315.md) | [(22.1)](/filings/0001193125-26-349315.md) | [(23.1)](/filings/0001193125-26-349315.md) | [(25.9)](/filings/0001193125-25-269428.md) | [(26.0)](/filings/0001193125-26-349315.md) | [10.8](/filings/0001193125-26-349315.md) | [14.9](/filings/0001193125-26-349315.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(339) d](/filings/0000950170-24-123534.md) | [(480) d](/filings/0000950170-25-029003.md) | [(5,307)](/filings/0000950170-25-066964.md) | [(3,778) d](/filings/0001320350-25-000004.md) | [3,153 d](/filings/0001193125-25-269428.md) | [3,657 d](/filings/0001193125-26-134587.md) | [(6,938)](/filings/0001193125-26-214571.md) | [(4,998) d](/filings/0001193125-26-349315.md) | [(3,513) d](/filings/0001193125-25-269428.md) | [618 d](/filings/0001193125-26-134587.md) | [(4,271)](/filings/0001193125-26-214571.md) | [(127) d](/filings/0001193125-26-349315.md) |
| Capital expenditure | $k | [2.0 d](/filings/0000950170-24-123534.md) | [45.0 d](/filings/0000950170-25-029003.md) | [20.0](/filings/0000950170-25-066964.md) | [113 d](/filings/0001320350-25-000004.md) | [20.0 d](/filings/0001193125-25-269428.md) | [3.0 d](/filings/0001193125-26-134587.md) | [6.0](/filings/0001193125-26-214571.md) | [77.0 d](/filings/0001193125-26-349315.md) | [0.0 d](/filings/0001193125-25-269428.md) | [0.0 d](/filings/0001193125-26-134587.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [10.2](/filings/0000950170-23-062153.md) | [10.7](/filings/0000950170-24-056837.md) | [10.8](/filings/0000950170-24-093862.md) | [12.0](/filings/0000950170-24-123534.md) | [11.4](/filings/0000950170-25-066964.md) | [11.5](/filings/0001320350-25-000004.md) | [11.6](/filings/0001193125-25-269428.md) | [11.8](/filings/0001193125-26-214571.md) | [11.9](/filings/0001193125-26-349315.md) | [12.0](/filings/0001193125-25-269428.md) | [15.4](/filings/0001193125-26-214571.md) | [23.0](/filings/0001193125-26-349315.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 12,285,865 at 2026-07-31, from the cover of the [10-Q filed 2026-08-13](/filings/0001193125-26-349315.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:36 ET. No prices; not investment advice.